GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Accounts Payable

3D Medicines (HKSE:01244) Accounts Payable : HK$58.4 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Accounts Payable?

3D Medicines's Accounts Payable for the quarter that ended in Jun. 2024 was HK$58.4 Mil.

3D Medicines's quarterly Accounts Payable increased from Jun. 2023 (HK$47.2 Mil) to Dec. 2023 (HK$78.6 Mil) but then declined from Dec. 2023 (HK$78.6 Mil) to Jun. 2024 (HK$58.4 Mil).

3D Medicines's annual Accounts Payable increased from Dec. 2021 (HK$4.6 Mil) to Dec. 2022 (HK$17.7 Mil) and increased from Dec. 2022 (HK$17.7 Mil) to Dec. 2023 (HK$78.6 Mil).


3D Medicines Accounts Payable Historical Data

The historical data trend for 3D Medicines's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Accounts Payable Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accounts Payable
2.86 4.58 17.73 78.64

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accounts Payable Get a 7-Day Free Trial - 17.73 47.22 78.64 58.39

3D Medicines Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


3D Medicines Accounts Payable Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines Headlines

No Headlines